OncoMatch/Clinical Trials/NCT07885423
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
Official title: Clinical Evaluation of the ACP3-Targeted Dual-Modality PET/Fluorescence Imaging Probe 68Ga-XMFH01 for Preoperative Imaging and Intraoperative Surgical Guidance in Prostate Cancer
Is NCT07885423 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for prostate cancer (diagnosis).
This study aims to evaluate the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative fluorescence-guided surgery in patients with prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: ≤2 months of ADT or conventional hormonal therapy allowed
More than 2 months of androgen deprivation therapy (ADT) or conventional hormonal therapy
Cannot have received: novel hormonal agent
any prior treatment with novel hormonal agents
Cannot have received: chemotherapy
any prior treatment with ... chemotherapy
Cannot have received: immunotherapy
any prior treatment with ... immunotherapy
Cannot have received: targeted therapy
any prior treatment with ... targeted therapy
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Cannot have received: surgery for prostate cancer
Prior ... surgery for prostate cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07885423 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy, novel hormonal agent, chemotherapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages